FY21: Aurobindo Pharma to unveil over 50 products in US
"We are expecting to launch around 50 to 60 products this year including injectables...Out of the 50 to 60 products that we are talking about, 25 products have already been approved," he said during the latest earnings call earlier this month.;
Hyderabad: Aurobindo Pharma is expected to launch 50 to 60 new products during the current year, N Govindarajan, managing director of the city-based drug maker has said. "We are expecting to launch around 50 to 60 products this year including injectables...Out of the 50 to 60 products that we are talking about, 25 products have already been approved," he said during the latest earnings call earlier this month.
Aurobindo Pharma's US business posted a growth of 27 per cent year-on-year to Rs 11,484 crore in FY20.
On a constant currency basis, it increased by 26 per cent year-on-year to around USD 1.62 billion led by improvement in volumes and new product launches.
The company has received final approval for six ANDAs (abbreviated new drug application) and launched four products in the fourth quarter of last fiscal.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.